(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
11 June 2020 (11.06.2020)

WIPO | PCT

(10) International Publication Number
WO 2020/115277 A1

(51) International Patent Classification:
C07K 16/24 (2006.01) *A61K 9/00* (2006.01)
A61K 39/00 (2006.01) *A61K 9/14* (2006.01)

(21) International Application Number:
PCT/EP2019/083992

(22) International Filing Date:
06 December 2019 (06.12.2019)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
PCT/EP2018/084057
07 December 2018 (07.12.2018) EP

(71) Applicant: **TILLOTTS PHARMA AG** [CH/CH]; Baslerstrasse 15, 4310 Rheinfelden (CH).

(72) Inventors: **FURRER, Esther Maria**; c/o Tillotts Pharma AG, Baslerstrasse 15, 4310 Rheinfelden (CH). **VARUM, Felipe**; c/o Tillotts Pharma AG, Baslerstrasse 15, 4310 Rheinfelden (CH). **BRAVO, Roberto**; c/o Tillotts Pharma AG, Baslerstrasse 15, 4310 Rheinfelden (CH). **SPLEISS, Johannes**; c/o Tillotts Pharma AG, Baslerstrasse 15, 4310 Rheinfelden (CH). **NEDELJKOVIC, Marijana**; c/o Tillotts Pharma AG, Baslerstrasse 15, 4310 Rheinfelden (CH). **GERSTNER, Ortrud**; c/o Tillotts Pharma AG, Baslerstrasse 15, 4310 Rheinfelden (CH). **BRUNO, Cristina**; c/o Tillotts Pharma AG, Baslerstrasse 15, 4310 Rheinfelden (CH).

(74) Agent: **KALHAMMER, Georg** et al.; LEDERER & KELLER, Unsöldstr. 2, 80538 München (DE).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report (Art. 21(3))*
— *with sequence listing part of description (Rule 5.2(a))*

WO 2020/115277 A1

(54) Title: TOPICAL TREATMENT OF IMMUNE CHECKPOINT INHIBITOR INDUCED DIARRHOEA, COLITIS OR ENTEROCOLITIS USING ANTIBODIES AND FRAGMENTS THEREOF

(57) Abstract: The present invention relates to the therapeutic topical use of compositions containing antibody molecules or functional fragments or derivatives specific to tumour necrosis factor alpha (TNFα), for treating or preventing immune checkpoint (ICP) inhibitor-induced adverse events.